Evidence map›Paper›PMID 25446678›Full record

ArticleNeuropharmacology2015

Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Xi-Ling Jiang, Hong-Wu Shen, Ai-Ming Yu

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Human CYP2D6 varies across the estrous cycle in brains of transgenic mice altering drug response.Progress in neuro-psychopharmacology & biological psychiatry · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. A narrative synthesis of research with 5-MeO-DMT.Journal of psychopharmacology (Oxford, England) · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xi-Ling JiangDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214-8033, USA.
Hong-Wu Shen
Ai-Ming Yu
University at Buffalo, State University of New York · USUniversity of California Davis Medical Center · US

Funding

Pharmacogenetics in indolealkylamine metabolism and drug interactionsR01DA021172 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI YU, AIMING · 2007 to 2011
$1.7M
NIDA NIH HHS R01 DA021172NIDA NIH HHS R01DA021172
6 · The paper itself

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are serotonin (5-HT) analogs often abused together, which alters thermoregulation that may indicate the severity of serotonin toxicity. Our recent studies have revealed that co-administration of monoamine oxidase inhibitor harmaline leads to greater and prolonged exposure to 5-HT agonist 5-MeO-DMT that might be influenced by cytochrome P450 2D6 (CYP2D6) status. This study was to define the effects of harmaline and 5-MeO-DMT on thermoregulation in wild-type and CYP2D6-humanized (Tg-CYP2D6) mice, as well as the involvement of 5-HT receptors. Animal core body temperatures were monitored noninvasively in the home cages after implantation of telemetry transmitters and administration of drugs. Harmaline (5 and 15 mg/kg, i.p.) alone was shown to induce hypothermia that was significantly affected by CYP2D6 status. In contrast, higher doses of 5-MeO-DMT (10 and 20 mg/kg) alone caused hyperthermia. Co-administration of harmaline (2, 5 or 15 mg/kg) remarkably potentiated the hyperthermia elicited by 5-MeO-DMT (2 or 10 mg/kg), which might be influenced by CYP2D6 status at certain dose combination. Interestingly, harmaline-induced hypothermia was only attenuated by 5-HT1A receptor antagonist WAY-100635, whereas 5-MeO-DMT- and harmaline-5-MeO-DMT-induced hyperthermia could be suppressed by either WAY-100635 or 5-HT2A receptor antagonists (MDL-100907 and ketanserin). Moreover, stress-induced hyperthermia under home cage conditions was not affected by WAY-100635 but surprisingly attenuated by MDL-100907 and ketanserin. Our results indicate that co-administration of monoamine oxidase inhibitor largely potentiates 5-MeO-DMT-induced hyperthermia that involves the activation of both 5-HT1A and 5-HT2A receptors. These findings shall provide insights into development of anxiolytic drugs and new strategies to relieve the lethal hyperthermia in serotonin toxicity.

Indexed as

AnimalsBody WeightCytochrome P-450 CYP2D6Dose-Response Relationship, DrugDrug SynergismFeverHarmalineMaleMethoxydimethyltryptaminesMiceMice, TransgenicMonoamine Oxidase InhibitorsReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2ASerotonin AgentsCytochrome P-450 CYP2D6HarmalineMethoxydimethyltryptaminesMonoamine Oxidase InhibitorsReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2ASerotonin Agents

Identifiers

PMID25446678
PMCPMC4310233
OpenAlexW2091016019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.